A phase II/III study of Roxadustat for the treatment of anemia in patients with myelodysplastic syndromes (MDS)

Trial Profile

A phase II/III study of Roxadustat for the treatment of anemia in patients with myelodysplastic syndromes (MDS)

Planning
Phase of Trial: Phase II/III

Latest Information Update: 09 May 2017

At a glance

  • Drugs Roxadustat (Primary)
  • Indications Anaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors FibroGen
  • Most Recent Events

    • 09 May 2017 According to a FibroGen media release, the company expects to initiate this trial in the fourth quarter of 2017.
    • 31 Mar 2017 According to a FibroGen media release, the company expects to initiate this trial in the second half of 2017.
    • 31 Mar 2017 According to a FibroGen media release, the China Food and Drug Administration (CFDA) has approved the Clinical Trial Application (CTA) in China for this trail.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top